Understanding immune signatures of kidney transplant recipients during and after COVID-19 infection may provide insight into management.
All articles by Natasha Persaud
The monoclonal antibody combination retained a neutralizing activity against the Omicron variants BA.1, and BA.2 in kidney transplant recipients.
Urologists appear more likely than other specialists to inappropriately treat uncomplicated cystitis, according to study findings.
Few real-world studies have investigated the risks of hematuria and proteinuria associated with rosuvastatin use.
Observational study findings highlight a “persistent and marked” association between hypertension and risk for severe COVID-19, even among fully vaccinated patients, according to investigators.
Coinfection increased mortality risk among kidney transplant recipients with COVID-19, a study found.
Nirmatrelvir/ritonavir is not current recommended for patients with CKD stage 4 or 5, but low-dose regimens could avoid adverse events, according to the authors of a recent editorial.
Adults with sickle cell trait had a variety of preexisting kidney conditions that may have contributed to unfavorable outcomes following COVID-19 infection.
Tissue inhibitor of metalloproteinases 2 (TIMP-2) and insulinlike growth factor binding protein 7 (IGFBP7) could be used for AKI staging.
Although valganciclovir is an effective CMV prophylactic agent after kidney transplantation, it is associated with significant side effects.